ARTICLE | Company News
Alteogen, Qilu deal
April 13, 2017 11:12 PM UTC
Alteogen granted Qilu exclusive, Chinese rights to develop and market ALT-L2, a biosimilar of cancer drug Herceptin trastuzumab from Roche (SIX:ROG; OCTQX:RHHBY, Basel, Switzerland). Alteogen is eligi...
BCIQ Target Profiles
Epidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu)